Related references
Note: Only part of the references are listed.Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
Carolyn A. Foster et al.
BRAIN PATHOLOGY (2009)
Ketoconazole Increases Fingolimod Blood Levels in a Drug Interaction via CYP4F2 Inhibition
John M. Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions
Ingo Bartholomaeus et al.
NATURE (2009)
Oral fingolimod (FTY720) in multiple sclerosis Two-year results of a phase II extension study
P. O'Connor et al.
NEUROLOGY (2009)
Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects
John M. Kovarik et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Fingolimod (FTY720) in severe hepatic impairment: Pharmacokinetics and relationship to markers of liver function
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Factors related with treatment adherence to interferon β and glatiramer acetate therapy in multiple sclerosis
L Río et al.
MULTIPLE SCLEROSIS (2005)
Self-Injection Anxiety Training: a treatment for patients unable to self-inject injectable medications
DC Mohr et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects
JM Kovarik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Multiple-dose FTY720: Tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate
MG Sanna et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Overview of FTY720 clinical pharmacokinetics and pharmacology
JM Kovarik et al.
THERAPEUTIC DRUG MONITORING (2004)
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
A Billich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study
BD Kahan et al.
TRANSPLANTATION (2003)
Interrupted therapy -: Stopping and switching of the β-interferons prescribed for MS
HL Tremlett et al.
NEUROLOGY (2003)
Clinical importance of the cytochromes P450
DW Nebert et al.
LANCET (2002)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Share Paper
